- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Extrapulmonary tuberculosis.
Displaying page 1 of 1.
EudraCT Number: 2020-003146-36 | Sponsor Protocol Number: RIAlta-1 | Start Date*: 2023-11-15 |
Sponsor Name:Vall d'Hebron Research Institute (VHIR) | ||
Full Title: Safety of Rifampicin at High Dose for the Treatment of Adult Subjects with Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis | ||
Medical condition: Pulmonary and extrapulmonary tuberculosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003562-42 | Sponsor Protocol Number: AdjuVIT v3 | Start Date*: 2006-09-27 | |||||||||||
Sponsor Name:Queen Mary, University of London | |||||||||||||
Full Title: Trial of Adjunctive Vitamin D in Tuberculosis Treatment (AdjuVIT) | |||||||||||||
Medical condition: Pulmonary tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003301-22 | Sponsor Protocol Number: AC-R6 | Start Date*: 2021-10-05 | |||||||||||
Sponsor Name:Archivel Farma S.L. | |||||||||||||
Full Title: A phase IIB study to explore the efficacy and safety of the concomitant administration of RUTIĀ® immunotherapy with the standard treatment in patients with TB (CONSTAN) | |||||||||||||
Medical condition: Pulmonary Tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001820-36 | Sponsor Protocol Number: 114886 | Start Date*: 2012-10-15 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A phase II observer blind, randomised, controlled study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicalsā candidate tuberculosis vaccine GSK 692342 when administered to ... | |||||||||||||
Medical condition: Vaccination against tuberculosis (TB) in adults aged 18 to 59 years with TB disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004473-25 | Sponsor Protocol Number: 242-12-232 | Start Date*: 2018-09-14 |
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | ||
Full Title: Phase 1, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Pat... | ||
Medical condition: Pediatric patients with multidrug-resistant tuberculosis (MDRTB) who are receiving an optimized background regimen (OBR) of Antituberculosis Drugs | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-004620-38 | Sponsor Protocol Number: 242-12-233 | Start Date*: 2019-01-14 |
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | ||
Full Title: Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therap... | ||
Medical condition: Pediatric patients with multidrug-resistant tuberculosis (MDR-TB) who are receiving an optimized background regimen (OBR) of antituberculosis drugs | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-005264-86 | Sponsor Protocol Number: 1182.98 | Start Date*: 2007-02-21 |
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | ||
Full Title: Safety, efficacy and Pharmacokinetics of tipRanavir boosted with low-dose ritonavir (TPV/r) 500 mg/200 mg BID IN a racially and Gender diverse HIV positive treatment experienced population with a p... | ||
Medical condition: The objective of this study is to demonstrate the safety and efficacy of TPV/r among a racially diverse HIV-positive population of females and males who are three-class (NRTI, NNRTI, and PI) experi... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) ES (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-005023-33 | Sponsor Protocol Number: 1182.99 | Start Date*: 2007-03-15 | |||||||||||
Sponsor Name:Boehringer Ingelheim France SAS | |||||||||||||
Full Title: Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot e... | |||||||||||||
Medical condition: Treatment with three-class (NRTI, NNRTI, and PI) experienced HIV positive patients with HCV or HBV co-infection, with a minimum of 3-months duration for each class and have documented resistance to... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PT (Prematurely Ended) ES (Completed) DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
